166 related articles for article (PubMed ID: 34600748)
1. Serological response with Heplisav-B® in prior Hepatitis B vaccine non-responders living with HIV.
Khaimova R; Fischetti B; Cope R; Berkowitz L; Bakshi A
Vaccine; 2021 Oct; 39(44):6529-6534. PubMed ID: 34600748
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
Kuan RK; Janssen R; Heyward W; Bennett S; Nordyke R
Vaccine; 2013 Aug; 31(37):4024-32. PubMed ID: 23707166
[TBL] [Abstract][Full Text] [Related]
3. Two-Dose Hepatitis B Vaccine (Heplisav-B) Results in Better Seroconversion Than Three-Dose Vaccine (Engerix-B) in Chronic Liver Disease.
Amjad W; Alukal J; Zhang T; Maheshwari A; Thuluvath PJ
Dig Dis Sci; 2021 Jun; 66(6):2101-2106. PubMed ID: 32617767
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Heplisav-B Seroprotection in People With HIV: A Single-Center Experience.
Schnittman SR; Zepf R; Cocohoba J; Sears D
J Acquir Immune Defic Syndr; 2021 Apr; 86(4):445-449. PubMed ID: 33196553
[TBL] [Abstract][Full Text] [Related]
5. CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update.
Lee GH; Lim SG
Expert Rev Vaccines; 2021 May; 20(5):487-495. PubMed ID: 33783302
[No Abstract] [Full Text] [Related]
6. Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations.
Rosenthal EM; Hall EW; Rosenberg ES; Harris A; Nelson NP; Schillie S
Vaccine; 2020 Dec; 38(51):8206-8215. PubMed ID: 33160756
[TBL] [Abstract][Full Text] [Related]
7. Seroconversion following Heplisav-B, hepatitis B vaccine (recombinant), adjuvanted, in patients with end-stage renal disease at an urban safety net hospital.
Walsh C; McDaniel K; Lindsey L; Johnson S; Walton T
Am J Health Syst Pharm; 2023 Nov; 80(Suppl 4):S130-S134. PubMed ID: 36681904
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease.
Kwon JY; Daoud ND; Hashash JG; Picco MF; Farraye FA
Inflamm Bowel Dis; 2023 Feb; 29(2):254-259. PubMed ID: 35468183
[TBL] [Abstract][Full Text] [Related]
9. A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis.
Manley HJ; Aweh G; Frament J; Ladik V; Lacson EK
Nephrol Dial Transplant; 2023 Feb; 38(2):447-454. PubMed ID: 35150277
[TBL] [Abstract][Full Text] [Related]
10. Adult immunization against hepatitis B: Does the number of jabs matter?
Oster G; Bornheimer R; Ottino K; Stevenson C; Lewin C; Janssen R
Vaccine; 2022 Jun; 40(26):3597-3604. PubMed ID: 35570079
[TBL] [Abstract][Full Text] [Related]
11. Heplisav-B vaccination for the prevention of hepatitis B virus infection in adults in the United States.
Splawn LM; Bailey CA; Medina JP; Cho JC
Drugs Today (Barc); 2018 Jul; 54(7):399-405. PubMed ID: 30090877
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines.
Coates T; Wilson R; Patrick G; André F; Watson V
Clin Ther; 2001 Mar; 23(3):392-403. PubMed ID: 11318074
[TBL] [Abstract][Full Text] [Related]
13. Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
Girndt M; Houser P; Manllo-Karim R; Ervin JE; Charytan C; Chow S; Symonian-Silver M; Lehrner L; Linfert D; Shemin D; Michelsen A; Xie F; Janssen RS
Vaccine; 2023 May; 41(20):3224-3232. PubMed ID: 37085451
[TBL] [Abstract][Full Text] [Related]
14. Long-term protection after hepatitis B vaccination in people living with HIV.
Lara AN; Sartori AM; Fonseca MO; Lopes MH
Vaccine; 2017 Jul; 35(33):4155-4161. PubMed ID: 28669615
[TBL] [Abstract][Full Text] [Related]
15. Strategies for Hepatitis B Virus Prevention in People Living with HIV.
Corcorran MA; Kim HN
Curr HIV/AIDS Rep; 2023 Dec; 20(6):451-457. PubMed ID: 37837570
[TBL] [Abstract][Full Text] [Related]
16. Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations.
Hirst A; Hyer RN; Janssen RS
Vaccine; 2021 Jul; 39(33):4733-4741. PubMed ID: 34030898
[TBL] [Abstract][Full Text] [Related]
17. Heplisav-B in Prior Hepatitis B Vaccine Nonresponders: A Case Series.
Williams AL
Mil Med; 2022 Jul; 187(7-8):e811-e813. PubMed ID: 34557923
[TBL] [Abstract][Full Text] [Related]
18. CD4/CD8 ratio as a predictor of the response to HBV vaccination in HIV-positive patients: A prospective cohort study.
Fuster F; Vargas JI; Jensen D; Sarmiento V; Acuña P; Peirano F; Fuster F; Arab JP; Martínez F;
Vaccine; 2016 Apr; 34(16):1889-95. PubMed ID: 26945101
[TBL] [Abstract][Full Text] [Related]
19. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B
Elhanan E; Boaz M; Schwartz I; Schwartz D; Chernin G; Soetendorp H; Gal Oz A; Agbaria A; Weinstein T
Clin Exp Nephrol; 2018 Feb; 22(1):151-158. PubMed ID: 28456864
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients.
el-Reshaid K; al-Mufti S; Johny KV; Sugathan TN
Vaccine; 1994; 12(3):223-34. PubMed ID: 8165854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
